Trimedyne Inc. (OTCMKTS:TMED) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.

Trimedyne (TMED) remained flat at $4.25 during mid-day trading on Tuesday. 4 shares of the company’s stock were exchanged. Trimedyne has a 52 week low of $1.25 and a 52 week high of $6.75. The stock’s market cap is $518500.00. The stock has a 50-day moving average of $4.25 and a 200 day moving average of $4.11.

ILLEGAL ACTIVITY WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at

Trimedyne Company Profile

Trimedyne, Inc is engaged in the development, manufacturing and marketing of 80 and 30 watt Holmium cold pulsed lasers (Lasers). The Company’s segments include Product, and Service and Rental. It also offers a range of disposable and reusable, fiber optic laser energy delivery devices (Fibers, Needles and Switch Tips) for use in an array of medical applications.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Trimedyne Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trimedyne Inc. and related companies with's FREE daily email newsletter.